Clinical trials
Other Cancer clinical trials
Below are recruiting other cancer clinical trials, each written for real people, not researchers. We’re tracking 13,144 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06508567Recruiting
MRI-Guided Internal Radiation for Returning Prostate Cancer
This trial tests a new way to use a type of internal radiation (high-dose-rate brachytherapy) guided by MRI to treat prostate cancer that has come back in the same area after previous radiation therapy. It is designed to be more precise and hopefully safer while using the latest PSMA PET scans to make sure the cancer hasn't spread.
Toronto, OntarioAges 18 years+ - NCT06510543Recruiting
Nutrition drink before and after esophageal cancer surgery
This study tests a special nutrition drink (ORAL IMPACT®) before and after esophageal cancer surgery. It aims to help patients who are malnourished get stronger and recover better.
Beijing, Beijing MunicipalityAges 18–80 - NCT06511037RecruitingEarly Phase 1
Dye injection to help see cancer during belly surgery
This study tests a special dye, called pafolacianine, that is injected before surgery to help surgeons see hidden cancer spots in the belly during the operation. The goal is to see if using this dye improves how completely the cancer is removed in people with gastrointestinal cancer that has spread to the belly lining.
Orange, CaliforniaAges 18 years+ - NCT06511648RecruitingPhase 2
Erdafitinib with or without immunotherapy for FGFR-altered bladder cancer
This trial tests a targeted therapy called erdafitinib, either alone or combined with an immunotherapy drug (cetrelimab), for people with muscle-invasive bladder cancer that has a specific FGFR gene change. It may be an option if you cannot take cisplatin chemotherapy and have not had prior treatment for this cancer.
Clermont-FerrandAges 18 years+ - NCT06511674Recruiting
Nerve pain risk study for cancer patients
This study looks at why some people with cancer develop nerve pain (neuropathic pain) during treatment. By tracking your health and symptoms, researchers hope to find ways to predict and prevent this side effect.
AjaccioAges 18 years+ - NCT06512051RecruitingPhase 1/Phase 2
Study of SHR-A2102 and Adebrelimab for advanced lung cancer
This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, with or without other treatments, for people with advanced or metastatic non-small cell lung cancer that cannot be removed by surgery or cured with radiation. It aims to see if this approach can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–70 - NCT06512350Recruiting
Breath test for breast cancer patterns
This study is testing whether a simple breath test can help find patterns linked to breast cancer. If you are scheduled for a breast biopsy or MRI, you may be eligible to participate.
Washington D.C., District of ColumbiaAges 40–74 - NCT06513598Recruiting
Finding infection signs after abdominal cancer surgery
This study looks for ways to better predict and catch infections after major abdominal cancer surgery. If you are having surgery for certain cancers (esophagus, stomach, pancreas, liver, bile ducts, colon, or rectum), the researchers will check your blood and other samples for early signs of infection so they can start treatment sooner.
VilniusAges 18 years+ - NCT06514118Recruiting
Immunotherapy with radiation for advanced small-cell lung cancer
This trial tests a combination of chemotherapy, immunotherapy, and targeted radiation for people with extensive-stage small-cell lung cancer. The goal is to see if adding radiation to leftover tumors after initial treatment helps control the disease better.
Qingdao, ShandongAges 18–80 - NCT06515470RecruitingPhase 1
Testing BTX-9341 for advanced breast cancer
This trial tests a new oral drug, BTX-9341, for people with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have already had certain treatments, including a CDK4/6 inhibitor. The goal is to see if it is safe and effective.
Rochester, MinnesotaAges 18 years+ - NCT06515964Recruiting
Long-term study of early esophageal cancer after endoscopic surgery
This study follows people who had early-stage esophageal cancer removed with a minimally invasive procedure (ESD) to see how they do over time. It aims to understand how often the cancer comes back or spreads, and what factors might affect that.
Shanghai, Shanghai MunicipalityAges 15–85 - NCT06517901Recruiting
Comparing two MRI-guided biopsy methods for prostate cancer
This trial compares two ways to use MRI images during a prostate biopsy to see which finds cancer better. It looks at 'fusion' biopsy (where a computer combines MRI with live ultrasound) versus 'cognitive' biopsy (where the doctor mentally matches the MRI to the ultrasound).
Burlington, MassachusettsAges 18 years+ - NCT06517979Recruiting
AI model to detect cancer spread to lymph nodes
This trial uses artificial intelligence to analyze digital images of tumor tissue to see if cancer has spread to nearby lymph nodes. It aims to improve diagnosis for many types of cancer.
Guangzhou, GuangdongAges Any age - NCT06518226Recruiting
Ultra-short radiation with focal boost for prostate cancer
This trial tests a new, shorter course of radiation for intermediate-risk prostate cancer. It aims to give a higher dose to the main tumor while keeping side effects low.
UtrechtAges 18 years+ - NCT06518564RecruitingPhase 2
Avelumab and M1774 for ARID1A-mutated endometrial cancer
This trial tests a combination of two drugs, avelumab (an immunotherapy) and M1774, in people with a specific type of endometrial cancer that has an ARID1A gene mutation. The goal is to see if this combination can shrink tumors or slow cancer growth.
Boston, MassachusettsAges 18 years+ - NCT06519292Recruiting
Heart side effects from immunotherapy in cancer patients
This trial looks at whether immunotherapy drugs (checkpoint inhibitors) cause heart problems in people with certain cancers. It will help doctors understand who is at risk and how to monitor for side effects.
Amsterdam, North HollandAges 50 years+ - NCT06520683RecruitingPhase 3
Immunotherapy after surgery for high-risk stage II colorectal cancer
This trial tests whether a drug called an immune checkpoint inhibitor (PD-1 blocker) can help lower the risk of cancer returning after surgery. It is for people with a specific type of colorectal cancer (dMMR or MSI-H) that had certain high-risk features.
Guangzhou, GuangdongAges 18–80 - NCT06522256Recruiting
HPV and anal cancer risk 10 years later
This study looks at HPV (the virus that can cause anal cancer) and checks if certain types of high-risk HPV are linked to abnormal cells or cancer in the anus, 10 years after joining the IPERGAY trial. It helps researchers understand long-term risks.
LyonAges 18 years+ - NCT06523374Recruiting
Studying quality of life and cancer risk in Barrett's esophagus
This study looks at how Barrett's esophagus affects your quality of life and fear of cancer. It uses new tests to better predict who might develop esophageal cancer, so you can get the right care sooner.
Edegem, AntwerpenAges 18 years+ - NCT06523673RecruitingPhase 3
SBRT for lung cancer with limited new growth
This trial tests whether a precise type of radiation called SBRT can control lung cancer that has started to grow in only a few new spots while you are on standard treatments. It may help you delay changing to a different treatment.
Hangzhou, ZhejiangAges 18 years+ - NCT06524167Recruiting
Radiation therapy after surgery for advanced thyroid cancer
This study looks at whether adding radiation therapy after surgery can help people with thyroid cancer that is at high risk of coming back. It includes different types of thyroid cancer, like differentiated and medullary types.
ShanghaiAges 14–80 - NCT06524245Recruiting
Predicting Colorectal Cancer Recurrence with Portal Vein Blood
This study looks at blood from a special vein near your liver (portal vein) to find markers that might predict if colorectal cancer will come back. The goal is to create a better way to identify patients who may need closer monitoring after surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06525571RecruitingPhase 3
Blue light surgery for high-risk bladder cancer
This trial tests if using blue light during surgery helps remove all cancer in people with high-risk non-muscle invasive bladder cancer. It may lower the chance of the cancer coming back.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06526299RecruitingPhase 2
Higher dose of targeted radiation for prostate cancer with low PSMA levels
This trial tests a higher dose of a radioactive drug (177Lu-PSMA-617) for men whose prostate cancer has spread and does not produce much of a protein called PSMA on scans. The goal is to see if a stronger dose can work better than the standard dose.
San Francisco, CaliforniaAges 18 years+
Hear when a new Other Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for other cancer?
- Yes. Clin2 currently lists 13,144 recruiting other cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a other cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a other cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.